Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $22,221.68 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 7,432 shares of the company’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $22,221.68. Following the transaction, the insider now owns 165,061 shares of the company’s stock, valued at approximately $493,532.39. The trade was a 4.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tango Therapeutics Stock Down 2.7 %

Shares of NASDAQ TNGX opened at $3.26 on Friday. Tango Therapeutics, Inc. has a 12 month low of $2.59 and a 12 month high of $12.89. The business has a fifty day simple moving average of $3.14 and a 200-day simple moving average of $6.12.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TNGX. Guggenheim lowered their price objective on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. B. Riley decreased their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research note on Friday, November 8th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tango Therapeutics has a consensus rating of “Buy” and a consensus target price of $13.14.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds have recently modified their holdings of the stock. State Street Corp increased its holdings in shares of Tango Therapeutics by 26.8% during the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after acquiring an additional 489,949 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock valued at $10,538,000 after acquiring an additional 142,710 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Tango Therapeutics by 5.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock valued at $1,586,000 after buying an additional 26,192 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares during the last quarter. Finally, Congress Asset Management Co. grew its holdings in Tango Therapeutics by 9.0% in the 4th quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock valued at $704,000 after buying an additional 18,919 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.